ADJUVANT CHEMOTHERAPY OF PRIMARY OPERABLE LUMINAL B BREAST CANCER WITHOUT OVEREXPRESSION OF HER2/NEU IN POSTMENOPAUSAL WOMEN: YES OR NO?
Background. Luminal tumors account for 65 % of all breast cancer (BC) cases; however, within this group, there are multiple subtypes with various clinical and morphological characteristics, disease course and prognosis. Choosing an optimal strategy for adjuvant chemotherapy (ACT) in postmenopausal w...
Saved in:
Main Authors: | Yu. S. Shatova, V. V. Tokmakov, L. Yu. Vladimirova, L. N. Vaschenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2017-12-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/560 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expression of E- and N-cadherins in tumor in luminal, primary operable breast cancer without Her2/neu overexpression in postmenopausal women as a prognostic factor
by: V. V. Tokmakov, et al.
Published: (2020-12-01) -
ROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancer
by: V. O. Tarakanova, et al.
Published: (2022-06-01) -
Treatment of luminal HER2-negative breast cancer: opinion of experts
by: E. V. Artemeva, et al.
Published: (2024-06-01) -
MORPHOLOGICAL STUDY OF LUMINAL BREAST CANCER
by: M. V. Zavyalova, et al.
Published: (2016-02-01) -
Immunological and molecular genetic characteristics of luminal B breast cancer: a literature review
by: D. A. Ryabchikov, et al.
Published: (2017-02-01)